Besipirdine

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529711

CAS#: 119257-34-0

Description: Besipirdine, also known as HP-749 and P-867493, is an adrenergic receptor antagonist potentially for the treatment of overactive bladder.


Price and Availability

Size
Price

Size
Price

Size
Price

Besipirdine is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 529711
Name: Besipirdine
CAS#: 119257-34-0
Chemical Formula: C16H18ClN3
Exact Mass: 287.1189
Molecular Weight: 287.791
Elemental Analysis: C, 66.78; H, 6.30; Cl, 12.32; N, 14.60


Synonym: HP-749; P-867493; HP749; P867493; HP 749; P 867493

IUPAC/Chemical Name: N-propyl-N-(pyridin-4-yl)-1H-indol-1-amine hydrochloride

InChi Key: ZDFVWDHZXAGROF-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H17N3.ClH/c1-2-12-18(15-7-10-17-11-8-15)19-13-9-14-5-3-4-6-16(14)19;/h3-11,13H,2,12H2,1H3;1H

SMILES Code: CCCN(C1=CC=NC=C1)N2C=CC3=C2C=CC=C3.[H]Cl


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Pérez-Martínez FC, Vela-Navarrete R, Virseda J, Ocaña AV, Lluel P, Rekik M, Bienaymé H, Ferté J, Attali P, Palea S. Halothane-anesthetized rabbit: a new experimental model to test the effects of besipirdine and duloxetine on lower urinary tract function. Urol Int. 2011;86(2):210-9. doi: 10.1159/000321226. PubMed PMID: 21071917.

2: Hubbard JW, Nordstrom ST, Smith CP, Brooks KM, Laws-Ricker L, Zhou L, Vargas HM. alpha-Adrenergic activity and cardiovascular effects of besipirdine HCl (HP 749) and metabolite P7480 in vitro and in the conscious rat and dog. J Pharmacol Exp Ther. 1997 Apr;281(1):337-46. PubMed PMID: 9103515.

3: Huff FJ, Antuono PG, Delagandara JE, McDonald MA, Cutler NR, Cohen SR, Green RC, Zemlan FP, Crismon ML, Alter M, Shipley JE, Reichman WE. A treatment and withdrawal trial of besipirdine in Alzheimer disease. Alzheimer Dis Assoc Disord. 1996 Summer;10(2):93-102. PubMed PMID: 8727171.

4: Tang L, Smith CP, Huger FP, Kongsamut S. Effects of besipirdine at the voltage-dependent sodium channel. Br J Pharmacol. 1995 Nov;116(5):2468-72. PubMed PMID: 8581286; PubMed Central PMCID: PMC1909035.

5: Huff FJ. Preliminary evaluation of besipirdine for the treatment of Alzheimer's disease. Besipirdine Study Group. Ann N Y Acad Sci. 1996 Jan 17;777:410-4. PubMed PMID: 8624122.

6: Tang L, Kongsamut S. Frequency-dependent inhibition of neurotransmitter release by besipirdine and HP 184. Eur J Pharmacol. 1996 Apr 4;300(1-2):71-4. PubMed PMID: 8741167.

7: Sramek JJ, Viereck C, Huff FJ, Wardle T, Hourani J, Stewart JA, Cutler NR. A "bridging" (safety/tolerance) study of besipirdine hydrochloride in patients with Alzheimer's disease. Life Sci. 1995;57(12):1241-8. PubMed PMID: 7674813.

8: Woods-Kettelberger AT, Smith CP, Corbett R, Szewczak MR, Roehr JE, Bores GM, Klein JT, Kongsamut S. Besipirdine (HP 749) reduces schedule-induced polydipsia in rats. Brain Res Bull. 1996;41(2):125-30. PubMed PMID: 8879677.

9: Rao GP, Davis PJ. Microbial models of mammalian metabolism. Biotransformations of HP 749 (besipirdine) using Cunninghamella elegans. Drug Metab Dispos. 1997 Jun;25(6):709-15. Erratum in: Drug Metab Dispos 1997 Aug;25(8):1016. PubMed PMID: 9193872.

10: Klein JT, Davis L, Olsen GE, Wong GS, Huger FP, Smith CP, Petko WW, Cornfeldt M, Wilker JC, Blitzer RD, Landau E, Haroutunian V, Martin LL, Effland RC. Synthesis and structure-activity relationships of N-propyl-N-(4-pyridinyl)-1H-indol-1-amine (besipirdine) and related analogs as potential therapeutic agents for Alzheimer's disease. J Med Chem. 1996 Jan 19;39(2):570-81. PubMed PMID: 8558529.

11: Hubbard JW, Hsu RS, Griffiths L, Natarajan C, Dean R, Dileo EM, Hintze TH. The pharmacokinetics and cardiovascular pharmacodynamics of HP 749 (besipirdine HCl) and metabolite P86-7480 in the conscious monkey. J Clin Pharmacol. 1995 Jul;35(7):688-96. PubMed PMID: 7560249.

12: Smith CP, Huger FP, Petko W, Kongsamut S. HP 749 enhances calcium-independent release of [3H]norepinephrine from rat cortical slices and synaptosomes. Neurochem Res. 1994 Oct;19(10):1265-70. PubMed PMID: 7891842.

13: Hsu RS, DiLeo EM, Chesson SM, Klein JT, Effland RC. Determination of HP 749, a potential therapeutic agent for Alzheimer's disease, in plasma by high-performance liquid chromatography. J Chromatogr. 1991 Dec 6;572(1-2):352-9. PubMed PMID: 1818073.